Background: Dimethyl fumarate (DMF) alters the phenotype of circulating immune cells and causes lymphopenia in a subpopulation of treated multiple sclerosis (MS) patients. Objective: To phenotypically characterize circulating leukocytes in DMF-treated MS patients. Methods: Cross-sectional observational comparisons of peripheral blood from DMF-treated MS patients (n = 17 lymphopenic and n = 24 non-lymphopenic), untreated MS patients (n = 17) and healthy controls (n = 23); immunophenotyped using flow cytometry. Longitudinal samples were analyzed for 13 DMF-treated patients. Results: Lymphopenic DMF-treated patients had significantly fewer circulating CD8 + and CD4 + T cells, CD56 dim natural killer (NK) cells, CD19 + B cells and plasmacytoid dendritic cells when compared to controls. CXCR3 + and CCR6 + expression was disproportionately reduced among CD4 + T cells, while the proportion of T-regulatory (T-reg) cells was unchanged. DMF did not affect circulating CD56 hi NK cells, monocytes or myeloid dendritic cells. Whether lymphopenic or not, DMF-treated patients had a lower proportion of circulating central and effector memory T cells and concomitant expansion of naïve T cells compared to the controls. Conclusions: DMF shifts the immunophenotypes of circulating T cells, causing a reduction of memory cells and a relative expansion of naïve cells, regardless of the absolute lymphocyte count. This may represent one mechanism of action of the drug. Lymphopenic patients had a disproportionate loss of CD8 + T-cells, which may affect their immunocompetence.
Introduction
Dimethyl fumarate (DMF) was approved by the US Food and Drug Administration (FDA) in 2013 for the treatment of relapsing multiple sclerosis (MS). In clinical trials, absolute lymphocyte counts (ALC) typically dropped by about 30% and a subset of patients (5-6%) developed severe lymphopenia, with an ALC of < 500 cells/ul while on the drug. 1,2 DMFinduced lymphopenia is even more common in clinical practice. In a small clinical cohort, one-half of patients treated for > 12 months developed lymphocyte counts below the lower limit of normal; CD8+ T cells were preferentially lost. 3 In another study, older patients (> 55 years of age), patients with lower baseline ALC and patients with recent natalizumab (NTZ) exposure appeared to be at a higher risk of lymphopenia. 4 The mechanism by which DMF acts to reduce relapses in MS is multifactorial and may include lymphocyte depletion. Indeed, MS is viewed as a lymphocytemediated disease. 5 Depleting autoreactive cells and inhibiting their access to central nervous system (CNS) are known mechanisms for other MS diseasemodifying therapies (DMTs).
Nevertheless, lymphopenia is also a risk factor for infection. While opportunistic infections are uncommon, progressive multifocal leukoencephalopathy (PML) has been identified among patients taking DMF and related fumarate compounds. [6] [7] [8] [9] The affected patients were lymphopenic and had been treated with fumarates for years. Fatal West Nile virus encephalitis, disseminated Varicella zoster virus (VZV) and Kaposi's sarcoma (its infectious agent is Human Herpesvirus-8 (HHV-8)) have also been associated with fumarate use. [10] [11] [12] A better understanding of DMF-induced lymphopenia is necessary to understand the mechanism of this immune-modulating drug and to predict and manage complications that may arise with long-term use. To this end, we performed an extensive immunophenotypic analysis of blood leukocytes in lymphopenic and non-lymphopenic DMF-treated patients compared to untreated MS patients and healthy individuals.
Methods

Subject selection
This was a cross-sectional, observational study. We enrolled 41 MS patients who had been stable on 240 mg p.o. bid of DMF (Tecfidera, Biogen, Weston, MA, US) for ⩾ 6 months, including 17 patients with grade 2-3 lymphopenia (ALC of < 800 cells/µl), according to the common terminology criteria for adverse events. 13 Lymphopenic patients were specifically recruited. We also recruited 17 MS patients whom were not taking DMT and 23 healthy volunteers to serve as controls. We excluded patients who had received steroids within the last 3 months. Blood samples were drawn between 8:30 a.m. and 1:30 p.m. Expanded Disability Status Scale (EDSS) scores were retrospectively determined for MS patients based on their clinical documentation at the time of enrollment.
We obtained serial specimens from 13 subjects. The time between blood draws was 4-6 months (median: 6 months). Two patients made their initial donation after taking DMF for only 3-4 months; data from those initial samples were included only in the longitudinal portion of the analysis.
This study was approved by the Washington University Human Research Protection Office and all subjects provided written informed consent.
Leukocyte phenotyping
Fresh whole blood was labeled with CD25, CD45RA, CD45RO, CD86 (clone FUN-1) and CCR7 (clone 150503), all from BD Biosciences; Foxp3 (clone 259D), CXCR3 (clone G025H7), BDCA-2 (clone 201), BDCA-4 (clone 12C2), Lin-1, CD1c (clone L161), all from Biolegend; CCR6 (clone R6H1), CD56 (clone CMSSB), C14 (clone 61D3), CD3 (clone SK7), CD62L (clone DREG-56), all from eBioscience; and HLA-DR, CD4 and CD8, from Beckman Coulter. Fluorescent eBeads (eBioscience) were added to allow calculation of absolute cell numbers and flow cytometry was performed, using a Beckman Coulter Gallios instrument with 10 fluorescent channels.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 6 (La Jolla, CA, USA) and SPSS version 23.0 (IBM Corp, Armonk, NY, USA). Because most of the data were not normally distributed, comparisons between groups were performed using the Kruskal-Wallis analysis of variance (ANOVA) with Dunn's multiple comparison test for differences between groups. We also performed multiple linear regression analyses to control for age between the groups. Results were considered significant at p < 0.05.
Results
We performed flow cytometry analyses of peripheral immune cells in 41 DMF-treated MS patients, 17 untreated MS controls and 23 healthy controls (HCs) (Supplementary Table 1 ). The DMF-treated MS patients included 17 patients with grade 2-3 lymphopenia based on routine laboratory testing (DMF-treated patients with lymphopenia (DMF-L); mean ALC 594 cells/µl, range 300-800) and 24 patients with normal lymphocyte counts (DMFtreated patients with no lymphopenia (DMF-N); mean ALC 1493 cells/µl, range 900-3300). Groups had similar baseline demographics, including age (mean 46, range 25-69), gender and EDSS (median 2.75, range 0-6.5) (Supplementary Table 1 ). There were no significant differences between the DMF groups in terms of prior treatments (most patients had transitioned to DMF from interferons or glatiramer) or the number of prior DMTs. Lymphopenic patients had a slightly longer exposure to DMF compared to non-lymphopenic patients and had carried a diagnosis of MS for longer than the untreated MS controls (Supplementary Table 1 ). The duration of MS did not differ between the DMF-L and DMF-N patients.
Absolute cell counts for all T-lymphocyte populations, including CD4 + , CD8 + and T-regulatory cells (T-regs;
CD4 + CD25 + Foxp3 + ), were significantly reduced in DMF-L patients compared to the HC and MS controls (Figure 1 Table 1 ). We observed non-significant trends for lower T-lymphocyte counts in the DMF-N patients compared to the control Table 1 ).
Among other immune cell subsets, DMF-L patients had significantly fewer CD56 dim natural killer cells (NK cells, CD3 − CD56 dim ), as compared to HC and MS controls. The number of CD56 dim NK cells was also reduced in the DMF-N patients, as compared to HC (Figure 1 Table 1 ).
Given the variable treatment intervals, we subdivided the DMF-treated patients into those treated for 6-12 months (n = 11 for DMF-N and n = 5 for DMF-L) and those treated for >12 months (n = 16 for DMF-N and n = 12 for DMF-L; three patients contributed samples to both the 6-12-month subgroup and the >12-month subgroup). No significant differences between these groups were observed for any lymphocyte subset (data not shown).
Within the CD4 + and CD8 + lymphocyte subsets, we assessed the proportion of naïve, central memory (T CM ) and effector memory (T EM ) populations. DMF treatment was associated with relative expansion of the CD4 + and CD8 + naïve (CD45RA + CCR7 + ) T-cell subset, and with loss of the T CM (CD45RA − CCR7 + ) and T EM (CD45RA − CCR7 − ) subsets for both lymphopenic and non-lymphopenic patients (Table 2, Figure  2 (a) and Figure 2 (b)). We confirmed these findings by using an alternate method of identifying T CM (CD45RO + CD62L + ) and T EM (CD45RO + CD62L − ). Using this definition, we again observed that the fractions of circulating T CM and T EM were significantly decreased for both groups of DMF-treated patients when compared to healthy and MS controls with concurrent relative expansion of naïve T-cell populations ( Supplementary Figure 1 ). Analyses of serial blood samples from a subset of our cohort demonstrated that these lymphocyte populations were generally stable over time (Figure 2 (c) and Figure 2(d) ). A trend for recovery of the effector memory CD4 + T-cell population with time was observed in some subjects; the other T-cell subsets were unchanged during ongoing DMF exposure.
L-selectin (CD62L) is downregulated on T cells as they differentiate and become activated. Moreover, low numbers of circulating CD62L + CD4 + T cells may be a biomarker for PML risk among NTZ-treated patients. 14 Thus, circulating CD62L + CD4 + lymphocytes were compared between groups. Both DMF-L and DMF-N patients had an expansion of the CD62L + CD4 + lymphocyte population, compared to untreated MS controls and HC ( Table 2) .
Our cohort included a wide age range. Age was previously linked to DMF-induced lymphopenia 4 ; therefore, we performed multiple linear regression models to account for age. After controlling for age, DMF treatment remained a significant predictor for numbers of CD4 + and CD8 + T-cells, T-reg, CD56 dim NK (p ⩽ 0.001 for all) and for pDC (p = 0.004), as well as for the percentages of CD4 + and CD8 + naïve, T CM and T EM (p < 0.001 for all); however, DMF was not a significant predictor for CD19 + cell number after controlling for age (p = 0.123). Interestingly, age was an independent predictor of CD8 + (including naïve and T EM subsets) and pDC cells but did not contribute to other circulating lymphocyte subpopulations.
CXCR3 is considered a surrogate marker for CD4 + T-helper (Th) 1-type pro-inflammatory lymphocytes, while CCR6 is considered a surrogate marker for IL-17-producing Th17-type lymphocytes. Both subsets are thought to be pathogenic in MS. [15] [16] [17] We Figure 3 (a) and Figure 3(b) ). Despite the reduction in CD8 + numbers with DMF treatment, there were no changes in the proportion of CXCR3 or CCR6-expressing CD8+ T cells ( Figure  3 (c) and Figure 3(d) ).
Discussion
We performed extensive immunophenotyping of peripheral immune cells in DMF-L and DMF-N patients, as well as in HC and untreated MS controls, and demonstrated that there are reductions of multiple circulating immune cell subsets, particularly CD4 + and CD8 + T lymphocytes, among DMF-L patients. Moreover, we demonstrated that DMF treatment shifts the immunophenotype of circulating T cells, causing selective reductions of circulating central and effector memory CD4 + and CD8 + lymphocytes, regardless of absolute lymphocyte counts. These data may help elucidate the mechanism of action for DMF as well as provide additional information about the immunocompetence of patients taking DMF.
Memory T lymphocytes are responsible for mounting a rapid, robust immune response to a previously encountered antigen. In the healthy immune system, antigen-specific T EM rapidly migrate to areas of infection or inflammation and have an immediate effector function while T CM home to secondary lymphoid tissue, proliferate in response to antigenic stimulation, and then differentiate into T EM . Presumably, the majority of autoreactive T cells in MS are memory cells. 18 Indeed, this is the premise behind recent trials of stem cell transplants in MS; by eradicating the autoreactive memory populations and 'rebooting' the immune system using autologous stem cells, patients have achieved long-lasting remission and in some cases, reversal of disability. 19, 20 Depleting memory T cells may, therefore, be a key mechanism for DMF efficacy, analogous to an established mechanism of action for other MS therapies. Fingolimod depletes circulating naïve T cells and T CM 21 ; and the number of circulating T CM is a biomarker of response to fingolimod. 22 Similarly, we have now shown that DMF reduces circulating T CM in MS patients. Unlike fingolimod, DMF expands the proportion of naïve T cells in the circulation and reduces T EM .
Reduction in circulating CD62L + CD4 + lymphocytes is proposed as a possible biomarker of PML risk for NTZ-treated patients. Schwab et al. 14 showed that this T-cell subset was markedly diminished in NTZ-treated patients who subsequently developed PML when compared to controls and to NTZ-treated patients who did not develop PML. Given recent concerns about a possible PML risk with DMF therapy, we assessed this T-cell population among our cohort. We found that CD62L + CD4 + lymphocytes were relatively expanded among patients taking DMF. The role of L-selectin (CD62L) in MS is controversial 23 ; it is an adhesion molecule that is downregulated as the T cells mature and become activated. 24 Thus, the expansion of CD62L + populations in DMF-treated individuals parallels the expansion of naïve T cells. Whether the loss of circulating CD62L + CD4 + T cells is a biomarker for PML risk in DMF-treated patients deserves investigation. Indeed, the mechanism of DMF-induced T-cell redistribution requires further study. In vitro data suggest that fumarates induce T-cell apoptosis as well as impair lymphocyte proliferation and DC differentiation. 25, 26 Future studies should investigate lymphocyte differentiation and maturation in patients taking DMF to further explore the phenomenon of drug-induced T-lymphocyte redistribution.
We observed loss of several other immune subsets in DMF-treated patients when compared to controls. NK cells are subdivided into the CD56 dim population, which has enhanced killing activity, and the CD56 hi population, which secretes large amounts of cytokines but is not cytotoxic. 27 Recent work illustrates that CD56 hi NK-cells are immunoregulatory; these are expanded by daclizumab, a monoclonal antibody currently undergoing trials for MS. CD56 hi NK cell expansion is thought to contribute to the efficacy of daclizumab in MS. 28 Patients taking DMF maintained this immunomodulatory CD56 hi population. In contrast, CD56 dim NK cells were decreased in both lymphopenic and non-lymphopenic patients. Little is known about the role of CD56 dim NK cells in MS, although one study suggests that this population expands in progressive MS. 29 We also observed a modest decrease in pDCs among DMF-L patients compared to HC. This versatile cell type performs many immune functions, including production of Type 1 interferons; pDCs may be either immunogenic or tolerogenic, depending on their specific microenvironment. 30 pDCs have been identified in MS lesions, but their role in the disease remains controversial. 31 Further study is needed to confirm these findings and to explore the possible functional consequences.
In addition to altering T-lymphocyte subpopulations and depleting multiple types of circulating immune cells, DMF selectively reduced the proportion of circulating CXCR3 + CD4 + and CCR6 + CD4 + cells, but not T-regs, among lymphopenic patients. The CXCR3 + CD4 + population was also reduced in DMF-N patients. These chemokine receptors are sometimes considered surrogate markers for Th1-and Th17-type pro-inflammatory lymphocytes, respectively; both T-cell subsets have been implicated in MS pathogenesis. [15] [16] [17] Selective depletion of Th1 and Th17 cells would be expected to be protective in MS and could contribute to the therapeutic effect of DMF. Nevertheless, despite the loss of CXCR3 + and CCR6 + cells among DMF-L patients, these patients have not shown a superior clinical response to the drug to date. 4, 32 Spencer et al. 3 recently addressed DMF-induced immunophenotypic changes in a small cohort of patients that was followed longitudinally. Like us, they found a disproportionate reduction in CD8 + T cells relative to CD4 + T cells. They also reported time-dependent reductions in CD8 + , CD4 + and CD19 + lymphocytes, with no alteration in the levels of CD56 + NK cells, monocytes and other white blood cell (WBC) types. They did not examine T-cell subsets (i.e. regulatory or memory T-cell populations). Our cross-sectional observational study covered a larger group of subjects and was designed to include DMFtreated patients with and without clinical lymphopenia, as well as untreated MS controls and HC. We confirmed reductions in CD8+ T cells and CD4+ T cells, as well as a slight reduction in CD19 + B cell numbers when compared to controls; after controlling for age, however, DMF treatment did not affect CD19 + cell numbers. Although Spencer et al. 3 demonstrated a reduction in CD19 + cells over time, the absolute cell numbers typically remained within normal limits. Thus, the apparent discrepancy between our results is likely attributable to a longitudinal versus cross-sectional study design. Our phenotyping of T-reg, naïve, central memory and effector memory T-cell subsets, CD56 hi versus CD56 dim NK cells and DCs greatly extends the findings that were previously reported.
Few opportunistic infections have been reported with DMF. Despite this, the observed reductions of several WBC types suggests that clinicians should maintain vigilance. Concerns remain about the long-term safety of reducing T lymphocytes in general, and memory T cells in particular. CD4 + T-cell depletion is associated with a variety of opportunistic infections. 33, 34 CD8 + T cells are the major effectors of viral immunity and contribute to immune surveillance of the CNS. 35 It is possible that viral infections may become more prevalent in the setting of DMF-associated CD8 + T-cell reduction; recent reports of West Nile encephalitis and disseminated VZV in DMF-treated patients substantiate this. 10, 11 Redistributing naïve and memory T-lymphocyte populations relative to one another is also likely to have functional consequences. 36 Our data are limited by the cross sectional, observational design of this study. Although serial data from a subset of our study group on DMF for 3 months or more demonstrated stability of lymphocyte subsets during therapy, pre-treatment immunophenotyping was not available. Examination of the recovery of immune cell phenotypes after discontinuation of DMF over time would have been desirable as well, but these data would be difficult to interpret, as patients who stopped DMF due to lymphopenia typically begin other DMTs immediately thereafter. Moreover, we assessed circulating lymphocytes. It is possible that DMF alters immune cell compartmentalization and that lymphocytes are merely being redirected to another location rather than being permanently lost. Additional work will need to identify the mechanisms of DMF-induced lymphopenia and selective memory T-cell loss as well as any functional consequences.
In summary, we have shown that DMF induced redistribution of CD4 + and CD8 + naïve and memory T cells, with relative loss of circulating T CM and T EM cells in patients exposed to the drug regardless of their absolute lymphocyte count. Moreover, DMF caused loss of CD4 + and CD8 + T-lymphocytes from the bloodstream, with particular reductions of the Th1 and Th17-like cells, in a subset of MS patients.
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